Darbepoetin plus slow-release IntraVenous Iron to decrease transfusions and improve iron status and neurodevelopment...

Area of Science:

• Neonatal Medicine
• Hematology
• Developmental Pediatrics

Background:

• Preterm infants face high risks of anemia, iron deficiency, and transfusions, impacting neurodevelopment.
• Erythropoietic-stimulating agents and intravenous iron are potential interventions.

Purpose of the Study:

• To evaluate the safety and efficacy of darbepoetin combined with slow-release intravenous iron (ferumoxytol or low-molecular-weight iron dextran) in preterm infants.
• To determine the optimal iron preparation and dosage for maintaining iron sufficiency and reducing transfusions.
• To assess the impact of these treatments on the gut microbiome and neurodevelopment.

Main Methods:

• A randomized controlled Phase II trial involving 120 preterm infants (24-0/7 to 31-6/7 weeks gestation).
• Infants were randomized into five groups: oral iron (standard care) or weekly darbepoetin with varying doses of ferumoxytol or low-molecular-weight iron dextran.
• Outcomes include ferritin levels, hematologic assessments, drug safety, microbiome analysis, and neurodevelopmental testing up to 2 years corrected age.

Main Results:

• Primary outcome is ferritin level at 34-36 weeks postmenstrual age.
• Secondary outcomes include transfusion rates, safety, microbiome diversity, and neurodevelopmental trajectories.
• The study is ongoing, and results are pending.

Conclusions:

• This trial will provide crucial data on the safety and effectiveness of novel iron supplementation strategies in preterm infants.
• Findings will inform clinical practice regarding anemia management and its long-term effects on neurodevelopment.
• The study will elucidate the relationship between intravenous iron, gut microbiome, and neurodevelopmental outcomes.